---
schema_version: "secwatch.filing_event.v1"
accession: "0001789769-24-000020"
form_type: "8-K"
ticker: "TIL"
cik: "0001789769"
company_name: "Instil Bio, Inc."
filed_at: "2024-01-18T23:59:59+00:00"
generated_at: "2026-06-06T22:01:37.970593+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Instil Bio enters collaboration for ITIL-306 preclinical manufacturing feasibility studies

## Summary
- Agreement with collaborator for preclinical manufacturing feasibility studies on ITIL-306 program.
- Aims to enroll patients in investigator-initiated clinical trials (IITs).
- No guidance provided on timing of data readout for ITIL-306 or IIT studies.
- Forward-looking statements subject to risks including manufacturing and enrollment uncertainties.

## SEC filing metadata
- accession: 0001789769-24-000020
- form_type: 8-K
- ticker: TIL
- cik: 0001789769
- company_name: Instil Bio, Inc.
- filed_at: 2024-01-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789769/000178976924000020/0001789769-24-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789769/000178976924000020/til-20240117.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001789769-24-000020
- JSON: https://secwatch.observer/filing/0001789769-24-000020.json
- Plain text: https://secwatch.observer/filing/0001789769-24-000020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.